Diaceutics (DXRX) Share Price, News & Analysis

Company Overview

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

Key Stats

• Today's Range: 138.58 to 144
• 50-Day Range: 107.84 to 140
• 52-Week Range: 106 to 151
• Volume: 518,380 shs
• Average Volume: 128,858 shs
• Market Capitalization: £117.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: GBX 160
• Consensus Rating: Buy

Diaceutics Stock Analysis - MarketRank™

Diaceutics scored higher than 33% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Diaceutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Diaceutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Diaceutics is -41.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Diaceutics is -41.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Diaceutics has a P/B Ratio of 3.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for DXRX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Diaceutics does not currently pay a dividend.

Dividend Growth

Diaceutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for DXRX.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Diaceutics has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Diaceutics this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for DXRX on MarketBeat in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Diaceutics insiders have sold 420,068.07% more of their company's stock than they have bought. Specifically, they have bought £149.94 in company stock and sold £630,000 in company stock.

Percentage Held by Insiders

34.30% of the stock of Diaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

52.38% of the stock of Diaceutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DXRX Stock Analysis - Frequently Asked Questions

How have DXRX shares performed this year?

Diaceutics' stock was trading at GBX 123 at the beginning of the year. Since then, DXRX shares have increased by 13.0% and is now trading at GBX 139.
View the best growth stocks for 2025 here.

How were Diaceutics' earnings last quarter?

Diaceutics PLC (LON:DXRX) announced its earnings results on Tuesday, May, 13th. The company reported ($2.02) EPS for the quarter. Diaceutics had a negative net margin of 10.90% and a negative trailing twelve-month return on equity of 7.15%.

How do I buy shares of Diaceutics?

Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Diaceutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Diaceutics investors own include 4D pharma (DDDD), Rolls-Royce Holdings plc (RR.L), Abcam (ABC), B&M European Value Retail (BME), BP (BP), Coats Group (COA) and genedrive (GDR).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 5/25/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: LON:DXRX
• CIK: N/A
• Web: www.diaceutics.com
• Phone: N/A
• Fax: N/A
• Employees: 151
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 160
• High Stock Price Target: GBX 160
• Low Stock Price Target: GBX 160
• Potential Upside/Downside: +15.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX (3.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 137.52
• P/E Growth: N/A
• Net Income: £-2,843,065.67
• Net Margins: -10.90%
• Pretax Margin: N/A
• Return on Equity: -7.15%
• Return on Assets: -6.06%

Debt

• Debt-to-Equity Ratio: 0.39
• Current Ratio: 4.85
• Quick Ratio: 9.92

Sales & Book Value

• Annual Sales: £26.08 million
• Price / Sales: 4.50
• Cash Flow: GBX 44.55 per share
• Price / Cash Flow: 3.12
• Book Value: GBX 45.87 per share
• Price / Book: 3.03

Miscellaneous

• Outstanding Shares: 84,393,829
• Free Float: N/A
• Market Cap: £117.31 million
• Optionable: Not Optionable
• Beta: 0.58